// App-Quantinova.ai

: Critical Care Outcomes of Patients with Hematologic Malignancy (HM) and Hematopoietic Cell Transplant (HCT): A Canadian Multicenter Prospective Study

Researchers

Presenter

  • L. Munshi

Principal Investigators

  • P. Palepu

  • S. Shah

  • S. Thyagu

  • M. Minden

  • M. E. Detsky

  • L. Burry

  • S. Mehta

Medical Centers

  • Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada,

  • Hematology/Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada,

  • Sinai Health System, Toronto, Ontario, Canada.

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Mount Sinai Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Nephrology

  • Infectious Diseases (ID)

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Acute respiratory failure

  • Alpha-thalassemia myelodysplasia syndrome

  • Hematological malignancies

  • Tumor lysis syndrome

  • Acute renal failure

  • Acute Leukemia

  • Cardiac arrest

  • Myelofibrosis

  • Septic shock

  • Lymphomas

  • Multiple Myeloma

  • Sepsis

Biomarkers

  • Hematocrit

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved